Y-mAbs Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Y-mAbs Therapeutics

03/05/2024 23:34

* Y-mAbs Therapeutics Inc  YMAB.OQ   YMAB.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 7 for
the period ending March 31 2024
    * The New York City-based  company is expected to report a
9.7% increase in revenue to $22.22 million from $20.25 million a
year ago, according to the mean estimate from 4 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for Y-mAbs Therapeutics Inc
is for
a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 4.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Y-mAbs
Therapeutics Inc is $22.00​, above​ its last closing price
of $17.25. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.20       -0.20      -0.02     Beat    90.1
 Sep. 30 2023  -0.18       -0.19      -0.18     Beat    3.7
 Jan. 1 0001   -0.24       -0.24      -0.14     Beat    42.1​
 Mar. 31 2023  -0.32       -0.32      -0.15     Beat    52.9
 ​​Dec.        -0.44       -0.46      0.03      Beat    106.6
 31 2022                                                
 Sep. 30 2022  -0.71       -0.71      -0.63     Beat    11.3​
 Jun. 30 2022  -0.67       -0.67      -0.94     Missed  -41.2
 Mar. 31 2022  -0.73       -0.72      -0.64     Beat    10.7
 This summary was machine generated May 3 at 22:34 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)